Fate Therapeutics
FATE
Fate Therapeutics (FATE) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.29
- EPS estimate
- −$0.35
- EPS surprise
- +17.33%
- Revenue surprise
- +120.65%
- Revenue
- $1.9M
- Revenue estimate
- $864,255.00
- Reported
- Aug 12, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 12, 2025 | −$0.35 | −$0.29 | +17.33% | $1.9M | SEC |
| Q1 2025 | May 13, 2025 | −$0.38 | −$0.32 | +16.51% | $1.6M | SEC |
| Q4 2024 | Mar 5, 2025 | −$0.43 | −$0.44 | −1.73% | $1.9M | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.42 | −$0.40 | +3.96% | $3.1M | SEC |
| Q2 2024 | Aug 13, 2024 | −$0.46 | −$0.33 | +28.80% | $6.8M | SEC |
| Q1 2024 | May 9, 2024 | −$0.47 | −$0.47 | +0.38% | $1.9M | SEC |
| Q4 2023 | Feb 26, 2024 | −$0.52 | −$0.45 | +13.83% | $1.7M | SEC |
| Q3 2023 | Nov 8, 2023 | −$0.56 | −$0.46 | +17.84% | $1.9M | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.59 | −$0.54 | +8.24% | $933,000.00 | SEC |
| Q1 2023 | May 3, 2023 | −$0.62 | −$0.19 | +69.50% | $59.0M | SEC |
| Q4 2022 | Feb 28, 2023 | −$0.86 | −$0.58 | +32.75% | $44.4M | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.90 | −$0.86 | +3.91% | $15.0M | SEC |
| Q2 2022 | Aug 3, 2022 | −$0.83 | −$0.79 | +4.72% | $18.5M | SEC |
| Q1 2022 | May 4, 2022 | −$0.77 | −$0.68 | +11.12% | $18.4M | SEC |
| Q4 2021 | Feb 28, 2022 | −$0.67 | −$0.72 | −8.09% | $17.1M | SEC |
| Q3 2021 | Nov 4, 2021 | −$0.57 | −$0.45 | +20.98% | $14.2M | SEC |
| Q2 2021 | Aug 4, 2021 | −$0.52 | −$0.58 | −11.60% | $13.4M | SEC |
| Q1 2021 | May 5, 2021 | −$0.43 | −$0.48 | −10.45% | $11.1M | SEC |
| Q4 2020 | Feb 24, 2021 | −$0.39 | −$0.61 | −55.18% | $15.9M | SEC |
| Q3 2020 | Nov 5, 2020 | −$0.33 | −$0.68 | −106.00% | $7.6M | SEC |
Quarterly revenue
Frequently asked questions
When did Fate Therapeutics (FATE) last report earnings?
Fate Therapeutics last reported on Aug 12, 2025, covering fiscal Q2 2025.
Did FATE beat earnings estimates?
Yes. Fate Therapeutics reported EPS of −$0.29 for Q2 2025 against a −$0.35 estimate — a 17.33% beat.
How much revenue did FATE report last quarter?
Fate Therapeutics reported $1.9M in revenue for Q2 2025, against a consensus estimate of $864,255.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.